Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer

Both paclitaxel and S-1 are effective against gastric cancer, but the optimal regimen for combined chemotherapy with these drugs remains unclear. This phase I/II study was designed to determine the maximum tolerated dose (MTD), recommended dose (RD), dose-limiting toxicity (DLT), and objective respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Mochiki, E, Ohno, T, Kamiyama, Y, Aihara, R, Haga, N, Ojima, H, Nakamura, J, Ohsawa, H, Nakabayashi, T, Takeuchi, K, Asao, T, Kuwano, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360766/
https://www.ncbi.nlm.nih.gov/pubmed/17133268
http://dx.doi.org/10.1038/sj.bjc.6603497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360766/
https://www.ncbi.nlm.nih.gov/pubmed/17133268
http://dx.doi.org/10.1038/sj.bjc.6603497

Ejemplares similares